# Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

> **NCT03533257** · PHASE2 · COMPLETED · sponsor: **Amylyx Pharmaceuticals Inc.** · enrollment: 95 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** AMX0035
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03533257
- **Lead sponsor:** Amylyx Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2020-10-22
- **Final completion:** 2020-11-06
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-03-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03533257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03533257, "Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03533257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*